| Market Cap | 487.65M | P/E | - | EPS this Y | -58.40% | Ern Qtrly Grth | - |
| Income | -17.88M | Forward P/E | -26.26 | EPS next Y | 29.50% | 50D Avg Chg | 8.00% |
| Sales | 370k | PEG | -0.51 | EPS past 5Y | - | 200D Avg Chg | 9.00% |
| Dividend | N/A | Price/Book | 22.83 | EPS next 5Y | 36.00% | 52W High Chg | - |
| Recommedations | 3.00 | Quick Ratio | 5.25 | Shares Outstanding | 21.60M | 52W Low Chg | 200.00% |
| Insider Own | 46.50% | ROA | -47.56% | Shares Float | 9.84M | Beta | 0.18 |
| Inst Own | 40.01% | ROE | -63.97% | Shares Shorted/Prior | 1.63M/1.74M | Price | 22.58 |
| Gross Margin | 7.03% | Profit Margin | - | Avg. Volume | 181,369 | Target Price | - |
| Oper. Margin | -6,421.35% | Earnings Date | Mar 2 | Volume | 1,347,169 | Change | 0.00% |
Soliton, Inc., a medical device company, develops and commercializes products using a proprietary rapid acoustic pulse technology platform. The company offers products for the removal of tattoos. It also develops a product for cellulite reduction, fibrotic scar treatment, and other indications. The company was incorporated in 2012 and is based in Houston, Texas. As of December 16, 2021, Soliton, Inc. operates as a subsidiary of Allergan plc.
| Roth Capital | Neutral | Jun 2, 21 |
| Cantor Fitzgerald | Neutral | May 13, 21 |
| Cantor Fitzgerald | Overweight | Jul 15, 20 |